All In Biotech

Free tool

FAERS Monitor: Sivextro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205436 or its brand name (Sivextro, Tedizolid Phosphate). Reports on generic versions are filed under their own applications.

Reports

803

Serious

528

66% of reports

Hospitalization

254

Death reported

51

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use110
  • product use in unapproved indication88
  • thrombocytopenia62
  • anaemia51
  • nausea45
  • no adverse event43
  • drug ineffective36
  • pancytopenia34
  • product availability issue33
  • product dose omission issue32
  • diarrhoea27
  • rash25
  • serotonin syndrome21
  • vomiting21
  • death19

Reports by year received

View as table
YearReports
201410
201539
201634
201741
201855
2019108
202083
202173
202262
2023109
202469
202572
202648

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,356 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product availability issueSignal3338.027.21,152
serotonin syndromeSignal2128.718.8533
pancytopeniaSignal3415.911.5462
thrombocytopeniaSignal6214.511.4771
product use in unapproved indicationSignal889.37.6651
anaemiaSignal517.05.4259
no adverse eventSignal436.24.6185
off label useSignal1103.32.8181
product dose omission issueSignal322.92.037
rash251.51.04
nausea451.51.17
vomiting211.20.80
diarrhoea271.10.80
drug ineffective360.70.54
death190.60.46

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.